Precipio (NASDAQ:PRPO) Posts Earnings Results

Precipio (NASDAQ:PRPO) issued its quarterly earnings results on Monday. The biotechnology company reported $0.34 earnings per share for the quarter, FiscalAI reports. Precipio had a negative return on equity of 2.89% and a negative net margin of 1.51%.The business had revenue of $6.70 million during the quarter.

Precipio Stock Up 5.2%

NASDAQ:PRPO opened at $25.14 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 1.10 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average of $24.88 and a 200-day moving average of $22.80. The firm has a market capitalization of $44.04 million, a PE ratio of -100.55 and a beta of 1.22. Precipio has a 52 week low of $3.90 and a 52 week high of $29.53.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRPO. AMH Equity Ltd lifted its stake in Precipio by 370.1% in the third quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock valued at $2,332,000 after buying an additional 103,210 shares during the last quarter. Topline Capital Management LLC acquired a new position in shares of Precipio during the third quarter valued at $1,158,000. Evernest Financial Advisors LLC bought a new position in shares of Precipio during the third quarter worth about $374,000. Susquehanna International Group LLP acquired a new stake in shares of Precipio in the 3rd quarter worth about $194,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Precipio by 10.7% in the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 1,400 shares during the period. Institutional investors and hedge funds own 10.45% of the company’s stock.

Analysts Set New Price Targets

PRPO has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precipio in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Precipio from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.